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There is no established treatment for patients with advanced hepatocellular carci-
noma (HCC) with Child–Pugh class B cirrhosis. The aim of the present study was
to assess the efficacy of hepatic arterial infusion chemotherapy (HAIC) according
to Child–Pugh score (CPS) and to evaluate the correlation of a patient’s response
to HAIC with hepatic reserve and outcome. We retrospectively reviewed the med-
ical records of 377 patients treated with HAIC between March 2003 and February
2015. Subjects included 179 with Child–Pugh class B. Median overall survival was
12.1 months for patients with CPS = 7 (n = 75) and 11.9 months for patients with
CPS = 8 (n = 58), which were significantly longer compared with those of
patients with CPS = 9 (n = 46, 6.3 months). The objective response rates of
patients with CPS = 7, 8 and 9 were 26.7%, 27.6% and 6.5%, respectively. The
CPS of responders improved significantly after HAIC, whereas those of nonre-
sponders did not. A multivariate analysis demonstrated that improved CPS,
responses to HAIC and absence of extrahepatic lesions were independent favor-
able prognostic factors. Patients with CPS = 7 or 8 tolerated HAIC, but nine
(19.6%) of patients with CPS = 9 were unable to complete one course. HAIC is
effective and safe for patients with a CPS = 7 or 8 and improved hepatic reserve
of responders significantly.
H epatocellular carcinoma (HCC) remains a health concernworldwide because its incidence continues to increase.(1)
Despite recent advances in diagnostic and therapeutic tech-
nologies,(2,3) patients with HCC who receive curative treatment
frequently experience multicentric recurrence that is difficult to
treat. Consequently, patients with advanced HCC have unsatis-
factory outcomes.(4)
For patients without cirrhosis or with Child–Pugh class A
cirrhosis, the results of a randomized trial establish sorafenib
as the standard of care for patients with advanced HCC.(5) In
contrast, there is no established treatment for patients with
advanced HCC with Child–Pugh class B cirrhosis. Sorafenib
may be a treatment option for patients with Child–Pugh class
B cirrhosis;(6) however, the outcomes of these patients are
worse compared with those with Child–Pugh class A.(7–10)
Therefore, the development of alternative treatments is
essential.
Hepatic arterial infusion chemotherapy (HAIC) is a promis-
ing treatment for a certain number of patients with advanced
HCC and is being administered in Asia in particular.(11) How-
ever, for example, to our knowledge, there are no reports that
evaluate the efficacy and feasibility of HAIC according to
Child–Pugh scores (CPS) and change of CPS of patients with
advanced HCC and Child–Pugh class B cirrhosis treated with
HAIC. The efficacy of HAIC for those patients remains
unclear.
The aim of the present study was to determine the efficacy
of HAIC for treating patients with advanced HCC with Child–
Pugh class B. Moreover, we investigated the effect of patients’
responses to treatment on their outcomes and hepatic reserves.
Materials and Methods
Objective patients. We studied consecutive patients with
advanced HCC who were treated with HAIC at the Kanazawa
University Hospital from March 2003 to February 2015.
Because the radiological findings of these patients included
vascular invasion and/or intrahepatic multiple lesions, they
were judged to be unsuitable for surgical resection, locore-
gional therapy and transarterial chemoembolization. All
patients underwent dynamic computed tomography or dynamic
magnetic resonance imaging, and HCC was diagnosed accord-
ing to the guidelines of the American Association for the
Study of Liver Disease.(12) Patients with extrahepatic lesions
were eligible for HAIC if their extrahepatic lesions were mild
and judged not to be prognostic (i.e. small tumor burden,
slowly growing tumor, and no effect of the tumor on patients’
symptoms).
Hepatic arterial infusion chemotherapy. The implantation of
the reservoir system to deliver agents is performed as previ-
ously described.(13) Briefly, catheters were induced through the
right femoral artery, and angiography from the celiac artery
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was first performed to localize the HCC and evaluate intrahep-
atic and extrahepatic vascularization. We next inserted a cathe-
ter with the side opening into the gastroduodenal artery,
positioning the side opening in the common hepatic artery
using an image-guided procedure. The gastroduodenal artery,
right gastric artery and other arteries that were suspected to
nourish the gastroduodenal region were embolized to the
extent possible to prevent gastrointestinal mucositis. The other
end of the catheter was connected to the injection port that
was implanted subcutaneously in the right-lower abdomen.
Finally, we confirmed the redistribution of blood flow.
Hepatic arterial infusion chemotherapy was conducted after
we confirmed the full recovery of the wound. The treatment
protocol was as follows: 5-fluorouracil (330 mg/m2/day) was
administered continuously from days 1 to 5 and days 8 to 12.
Some patients received intravenous cisplatin (20 mg/m2/day)
injected into the hepatic artery for 10 min before administra-
tion of 5-fluorouracil. Interferon a-2b or pegylated interferon
a-2b was used at the physician’s discretion. Pegylated inter-
feron a-2b (1.0 lg/kg) was administered subcutaneously on
days 1, 8, 15 and 22, and interferona-2b (3 9 106 U) was
administered intramuscularly three times each week. The drugs
were administered for a treatment cycle of 28 days followed
by a 14-day rest period. The treatment was repeated until
tumor progression, unacceptable toxicity, patient refusal of
treatment, or death.
Assessment of consequence by treatment. The efficacy of
treatment was assessed every 4–6 weeks using dynamic com-
puted tomography or dynamic magnetic resonance imaging
during and after treatment. The antitumor effect of treatment
was assessed according to the Response Evaluation Criteria in
Solid Tumors version 1.1.(14) The Child–Pugh score was
assessed every visit using physiological and laboratory find-
ings. Overall survival (OS) was defined as the start of treat-
ment until death. Progression-free survival (PFS) was defined
as the start of treatment until the date of radiological progres-
sion, death, or the last day of follow-up. An objective response
rate was defined as the sum of the complete response rate and
the partial response rate.
Data collection. We reviewed patients’ medical records and
collected demographic, clinical and laboratory data, which
included age, sex, Eastern Cooperative Oncology Group per-
formance status, hepatitis virus status, hepatic reserve, imaging
data (vascular invasion and extrahepatic lesions) and analyses
of tumor markers. The institutional review board of Kanazawa
University Hospital approved the study’s treatment strategy
and study protocol. The study was conducted in accordance
with the Declaration of Helsinki.
Statistical analysis. Categorical variables were compared
using the v2-test when appropriate. The Student t-test and the
Mann–Whitney test were used for continuous variables. Cumu-
lative survival was calculated using the Kaplan–Meier method
to evaluate the association of clinical factors with survival, and
differences were evaluated using the log-rank test. Multivariate
analysis using Cox’s proportional hazards regression model
was performed to determine the hazard ratios for risk factors
associated with OS. All statistical analyses were performed
using the SPSS statistical software program (version 21.0;
SPSS, Chicago, OH, USA).
Results
Characteristics of the patients treated with hepatic arterial
infusion chemotherapy. Between March 2003 and February
2015, 377 patients were treated with HAIC, and data were
collected until 14 March 2015. The median follow-up period
was 8.48 (range, 0.23–141.14) months. The Child–Pugh classi-
fications of patients when HAIC commenced were as follows:
A, 151 (40.1%); B, 179 (47.5%); and C, 47 (12.5%). Among
the patients with Child–Pugh class B, CPS were as follows:
CPS = 7, 75 (41.9%), CPS = 8, 58 (32.4%) and CPS = 9, 46
(25.7%). More patients with worse Child–Pugh classification
had a statistically significant increase in vascular invasion,
extrahepatic spread and a-fetoprotein (AFP) ≥400 ng/mL; and
more patients with worse Child–Pugh classification had more
advanced stages of HCC according to the criteria of the Liver
Cancer Study Group of Japan (Table 1). Patients with CPS = 9
were younger and had worse performance status compared
with patients with CPS = 7 or 8 (Table 2). Other patient
demographic characteristics are summarized in Tables 1 and 2.
At the time of the analysis, 291 patients (77.2%) were
deceased. The 377 patients completed a total of 965 courses of
treatment, with a median = 2 (range, 0–31). Eighteen patients
(10.1%), including three patients (4.0%) with CPS = 7, six
patients (10.3%) with CPS = 8, and nine patients (19.6%) with
CPS = 9, were unable to complete at least one course of HAIC
because of unacceptable toxicities, worse general condition or
tumor progression.
Progression-free survival and overall survival of patients trea-
ted with hepatic arterial infusion chemotherapy stratified accord-
ing to Child–Pugh score. The median PFS was 4.8, 4.1 or
1.4 months for patients with Child–Pugh class A, B or C,
respectively (Fig. 1a). The median PFS was 4.8, 4.9 and
1.7 months for patients with CPS = 7, 8 and 9, respectively.




A (n = 151)
Child–Pugh
class
B (n = 179)
Child–Pugh class
C (n = 47)
P-value*
Age, n (%)
≥66 88 (58.3) 93 (52.0) 16 (34.0) 0.015
Sex, n (%)
Male 123 (81.5) 135 (75.4) 37 (78.7) 0.41
ECOG PS, n (%)
0 140 (92.7) 130 (72.6) 29 (61.7) <0.01
1 11 (7.3) 44 (24.6) 11 (23.4)
≥2 0 5 (2.8) 7 (14.9)
HB antigen, n (%)
Positive 40 (26.5) 42 (23.5) 17 (36.2) 0.21
HCV antibody, n (%)
Positive 78 (51.7) 98 (54.7) 22 (46.8) 0.60
Vascular invasion, n (%)
Positive 64 (42.4) 93 (52.0) 31 (66.0) 0.014
Extrahepatic spread, n (%)
Positive 29 (19.2) 48 (26.8) 18 (38.3) 0.025
LCSGJ tumor stage, n (%)
II, III 85 (56.3) 85 (47.5) 16 (34.0) 0.064
IVA 47 (31.1) 56 (31.3) 16 (34.0)
IVB 19 (12.6) 38 (21.2) 15 (31.9)
AFP, n (%)
≥400 ng/mL 59 (39.1) 91 (50.8) 32 (68.1) <0.01
*v2-test. AFP, a-fetoprotein; ECOG PS, Eastern Cooperative Oncology
Group performance status; HB antigen, hepatitis B virus surface anti-
gen; HCV antibody, hepatitis C virus antibody; LCSGJ, Liver Cancer
Study Group of Japan.
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The PFS of patients with CPS = 7 and 8 was significantly
better compared with that of patients with CPS = 9
(P = 0.024 and P = 0.011 compared with CPS = 7 and 8,
respectively) (Fig. 1b).
The median OS was 15.5, 9.9 and 2.9 months for patients
with Child–Pugh class A, B and C, respectively (Fig. 2a). The
median OS was 12.1, 11.9 and 6.3 months for patients with
CPS = 7, 8 and 9, respectively. The OS of patients with
CPS = 7 and 8 was significantly better compared with that of
patients with CPS = 9 (P = 0.015 and P = 0.043 compared
with CPS = 7 and 8, respectively) (Fig. 2b).
Objective response to with hepatic arterial infusion chemother-
apy according to Child–Pugh score. The objective responses to
HAIC were 33.8%, 21.8% and 6.4% for patients with Child–
Pugh class A, B and C, respectively. For patients with
CPS = 7, 8 and 9, their objective responses to HAIC were
26.7%, 27.6% and 6.5%, respectively (Table 3). The objective
responses of patients with CPS of 7 and 8 were significantly
better compared with those of patients with CPS = 9
(P < 0.01 and P < 0.01 compared with CPS = 7 and 8,
respectively) (Table 4).
Analysis of Child–Pugh score of patients with Child–Pugh class
B stratified according to their responses to hepatic arterial infu-
sion chemotherapy. Among patients with Child–Pugh class B,
CPS data were available for 173 and 130 patients at 4 and
12 weeks, respectively, after HAIC started (Table S1). Among
patients with CPS = 7 when HAIC commenced, the CPS sig-
nificantly improved for responders to 6.45 after 4 weeks
(P < 0.01), which was maintained after 12 weeks (the mean
CPS 6.30, P < 0.01). In contrast, the CPS did not improve for
those whose best antitumor effect was stable disease; the mean
CPS after 4 and 12 weeks were 7.17 and 7.36, respectively,
among patients with CPS = 7 when HAIC commenced
(P = 0.58 and 0.10, respectively). Moreover, the CPS became
worse for those whose best antitumor effect was progressive
disease or not evaluable; the mean CPS after 4 and 12 weeks
were 7.38 and 7.88, respectively, among the patients with
CPS = 7 when HAIC commenced (P = 0.18 and 0.038,
respectively) (Fig. 3). Among patients with a CPS = 8 or 9
when HAIC commenced, the improvement of CPS for respon-
ders was similar to those of patients with CPS = 7 (Table S1).
Effects of hepatic arterial infusion chemotherapy on the Child–
Pugh score of patients with main portal vein tumor throm-
bus. Among patients with Child–Pugh class B, 59 had main
portal vein tumor thrombus when HAIC commenced. Nine
patients responded to HAIC, and the best antitumor effect was
stable disease for 17 patients. The other 33 patients had
Table 2. Demographic characteristic of the patients with Child–Pugh
B according to Child–Pugh score
Child–Pugh score
P-value*
7 (n = 75) 8 (n = 58) 9 (n = 46)
Age, n (%)
≥66 46 (61.3) 29 (50.0) 18 (39.1) 0.056
Sex, n (%)
Male 57 (76.0) 39 (67.2) 39 (84.8) 0.12
ECOG PS, n (%)
0 55 (73.3) 46 (79.3) 29 (63.0) 0.038
1 20 (26.7) 11 (19.0) 13 (28.3)
≥2 0 1 (1.7) 4 (8.7)
HBs antigen, n (%)
Positive 16 (21.3) 16 (27.6) 10 (21.7) 0.67
HCV antibody, n (%)
Positive 39 (52.0) 33 (56.9) 26 (56.5) 0.82
Vascular invasion, n (%)
Positive 36 (48.0) 31 (53.4) 26 (56.5) 0.64
Extrahepatic spread, n (%)
Positive 21 (28.0) 13 (22.4) 14 (30.4) 0.63
LCSGJ tumor stage, n (%)
II, III 40 (53.3) 28 (48.3) 17 (37.0) 0.68
IVA 20 (26.7) 17 (29.3) 19 (41.3)
IVB 15 (20.0) 13 (22.4) 10 (21.7)
AFP, n (%)
≥400 ng/mL 43 (57.3) 25 (43.1) 23 (50.0) 0.26
*v2-test. AFP, a-fetoprotein; ECOG PS, Eastern Cooperative Oncology
Group performance status; HB antigen, hepatitis B virus surface anti-
gen; HCV antibody, hepatitis C virus antibody; LCSGJ, Liver Cancer
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Fig. 1. Kaplan–Meier plot of progression-free survival after hepatic
arterial infusion chemotherapy commenced, according to Child–Pugh
classification and Child–Pugh score. (a) The median progression-free
survival was 4.8, 4.1 or 1.4 months for patients with Child–Pugh class
A, B and C, respectively. (b) The median progression-free survival of
the patients with Child–Pugh score = 7 was 4.8 months, which was
significantly better compared with that of patients with Child–Pugh
score = 9, 1.7 months (P = 0.024). The median progression-free sur-
vival of patients with Child–Pugh score = 8 was 4.9 months, which
was significantly better compared with that of patients with Child–
Pugh score = 9 (P = 0.011).
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progressive disease or were not evaluable. When the change in
CPS was stratified according to patients’ responses to HAIC,
CPS was improved for the responders to HAIC of seven
(77.8%) at 4 and 12 weeks (Table S2). In contrast, at these
same times, CPS was improved for six (35.3%) and five
patients (29.4%) whose best antitumor effect was stable dis-
ease and eleven (33.3%) and two (6.1%) whose best antitumor
effect was progressive disease or who were not evaluable
(Table S2).
Analysis of each factor for Child–Pugh score of patients strati-
fied according to their responses to with hepatic arterial infusion
chemotherapy. When the change in each factor for CPS was
evaluated individually, all factors tended to exhibit an
improvement for responder to HAIC, although it was difficult
to evaluate encephalopathy, because of the small number of
patients with this condition (Fig. 4). For example, the mean
albumin level ( SD) of responders was 3.04 ( 0.44) when
HAIC commenced and improved to 3.22 ( 0.46) after
12 weeks. In contrast, all factors associated with CPS did not
improve for those whose best antitumor effect was stable dis-
ease or for those with progressive disease or those who were
not evaluable (Fig. 4). For example, the mean albumin levels
of patients with stable disease were 2.95 ( 0.46) when HAIC
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Fig. 2. Kaplan–Meier plot of overall survival after hepatic arterial
infusion chemotherapy commenced, according to Child–Pugh class
and Child–Pugh score. (a) The median overall survival was 15.5, 9.9 or
2.9 months for patients with Child–Pugh class A, B and C, respectively.
(b) The median overall survival of the patients with Child–Pugh
score = 7 was 12.1 months, which was significantly better compared
with that of patients with Child–Pugh score = 9, 6.3 months
(P = 0.015). The median overall survival of patients with Child–Pugh
score = 8 was 11.9 months, which was significantly better compared
with that of patients with Child–Pugh score = 9 (P = 0.043).
Table 3. Objective responses to hepatic arterial infusion







A (n = 151)
Child–Pugh
class
B (n = 179)
Child–Pugh
class
C (n = 47)
Complete response 12 (7.9%) 5 (2.8%) 1 (2.1%)
Partial response 39 (25.8%) 34 (19.0%) 2 (4.3%)
Stable disease 54 (35.8%) 62 (34.6%) 13 (27.7%)
Progressive disease 42 (27.8%) 63 (35.2%) 18 (38.3%)




Data are presented as N (%). †Based on RECIST v1.1.
Table 4. Objective responses to hepatic arterial infusion






7 (n = 75) 8 (n = 58) 9 (n = 46)
Complete response 2 (2.7%) 2 (3.4%) 1 (2.2%)
Partial response 18 (24.0%) 14 (24.1%) 2 (4.3%)
Stable disease 23 (30.7%) 18 (31.0%) 16 (34.8%)
Progressive disease 28 (37.3%) 19 (32.8%) 21 (45.7%)




Data are presented as N (%). †Based on RECIST v1.1. ***P < 0.01
(v2-test) compared with the objective response rate for patients with
CPS = 9.
Fig. 3. Changes of Child–Pugh score ( SD) of patients with Child–
Pugh score = 7. The mean Child–Pugh scores of responders (circles and
black line) at 4 and 12 weeks after hepatic arterial infusion
chemotherapy commenced was significantly improved. For patients
whose best antitumor effects were stable (squares and gray line), the
mean Child–Pugh score did not improve. For patients whose best anti-
tumor effect was progressive disease or not evaluable (triangles and
dashed line), the mean Child–Pugh score became worse.
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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commenced, and the mean albumin levels of patients with pro-
gressive disease or those who were not evaluable were 2.96
( 0.44) when HAIC commenced, and 2.83 ( 0.58)
12 weeks after HAIC commenced.
Effects of with hepatic arterial infusion chemotherapy on over-
all survival and Child–Pugh score. When OS was stratified
according to patients’ responses to HAIC, those of responders
were significantly better compared with those of patients with
stable or progressive disease according to RECIST v1.1
(P < 0.001 and P < 0.001, respectively) (Fig. 5a). The median
OS of responders was 28.7 months, whereas that of the
patients with stable and progressive disease was 13.6 and
5.0 months, respectively. Similarly, the OS of the patients with
improved or unchanged CPS was significantly better compared
with patients with worsened CPS (P = 0.041 and P = 0.048)
(Fig. 5b). The median OS values of patients with improved,
unchanged and worsened CPS were 13.6, 13.2 and 4.3 months,
respectively. Improved CPS (hazard ratio compared with wors-
ened CPS, 0.609; P = 0.030), response to HAIC (hazard ratio
compared with progressive disease, 0.223; P < 0.001), stable
disease (hazard ratio, 0.537; P = 0.0031), and absence of
extrahepatic lesions (hazard ratio 0.543; P = 0.005) were iden-
tified as independent factors for favorable prognosis using a
multivariate Cox regression model (Table 5).
Discussion
Chronic liver disease is the underlying pathological condition
of most patients with HCC, and impaired hepatic reserve
caused by chronic liver disease often adversely affects a
patient’s outcome and quality of life.(15) Moreover, unlike
other types of cancer, a patient’s outcome strongly depends on
hepatic reserve as well as tumor factors which can be reflected
by tumor markers such as serum AFP levels.(16)
Novel targeted agents have been developed for patients
with advanced HCC, including drugs which are being inves-
tigated in the late-phase clinical trials. However, the study
populations are restricted to patients with sufficient hepatic
reserve, namely Child–Pugh class A, or those without
detectable liver cirrhosis.(17–19) These selective criteria were
imposed because of the difficulty in analyzing patients with
impaired hepatic reserve.(20) Furthermore, our present find-
ings indicate that the development of HCC, which was char-
acterized according to progressive intrahepatic lesions and
portal vein tumor thrombus, affected patients’ hepatic
reserve and that patients with more advanced stages of HCC
had increased impairment of hepatic reserve (Table 1). At
least 50% of the patients who underwent HAIC were diag-
nosed with Child–Pugh class B. Therefore, more effective
treatment strategies are urgently required to improve the out-




















































Fig. 4. Analysis of factors that influence the Child–Pugh score of
patients at 0 (baseline), 4 and 12 weeks after hepatic arterial infusion
chemotherapy commenced. All factors improved for responders (black
line), except for encephalopathy. In contrast, all factors did not
improve for those whose best antitumor effect was stable disease








0 24 48 72 96 120
(%)

































































































Number of paents at risk
Number of paents at risk
Fig. 5. Kaplan–Meier plot of overall survival after hepatic arterial
infusion chemotherapy commenced according to response and
changes in Child–Pugh score. (a) The median overall survival of a
patient whose best antitumor effect was a complete or partial
response, stable disease, or progressive disease or not evaluable was
28.7, 13.6 or 5.0 months, respectively. (b) The median overall survival
times of patients whose Child–Pugh scores were improved, unchanged
or worsened were 13.6, 13.2 or 4.3 months, respectively.
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In an attempt to overcome this difficult challenge, the first
aim of the present study was to investigate the feasibility
and efficacy of HAIC according to detailed CPS in patients
with Child–Pugh class B. Published studies of small num-
bers of patients with advanced HCC and Child–Pugh class
B who underwent HAIC did not analyze the relationship of
efficacy or tolerability to every aspect of the CPS.(21–23)
They concluded that the effectiveness of HAIC, according to
response or time to progression of patients with Child–Pugh
class B, was comparable with that of patients with Child–
Pugh class A. In contrast, the OS of the patients with
Child–Pugh class B was worse compared with those with
Child–Pugh class A. Our present findings are consistent with
those of the reports for patients with a CPS = 7 or 8;(21,22)
however, the responses to HAIC and the outcomes of
patients with CPS = 9 were significantly worse compared
with those with Child–Pugh class A or CPS = 7 or 8 and
were equal to those with Child–Pugh class C. Moreover, the
high rate of discontinuation (approximately 20%) during the
first course of HAIC demands careful attention for patients
with CPS = 9 and suggests that appropriate candidates for
HAIC were patients with a CPS 8 or better. In contrast, for
patients with a CPS 9 or worse, the efficacy of HAIC was
very limited, and patients’ outcomes were very poor.
The most important insight provided by our current study
is that a response to HAIC improved hepatic reserve, which
contributed to prolonging survival. In previous reports, the
clinical benefit of a response to treatment has been only
assessed in the context of survival prolongation.(24) To our
knowledge, the present study is the first to demonstrate a
significant merit to hepatic reserve by HAIC treatment to
HCC and the influence of the improvement of hepatic
reserve. Progressive intrahepatic lesions and portal vein
tumor thrombus can often lead to impairment of hepatic
reserve in part, as described above. For example, a main
portal vein tumor thrombus may disturb portal blood flow
and adversely affect liver function, which is consistent with
our findings, because shrinkage of the lesions contributes to
the improving hepatic reserve by mitigating the effects of
tumor localization on hepatic reserve. Moreover, improve-
ment of hepatic reserve may increase treatment options, such
as administering sorafenib to patients with Child–Pugh class
A. Thus, such therapies can contribute to controlling tumor
progression, although sufficient hepatic reserve is a favorable
prognostic factor itself. The treatment for patients with
advanced HCC should aim at relief from discomfort due to
the impaired hepatic function as well as outcomes of sur-
vival. Hepatic reserve closely correlates with quality of life
of patients with chronic liver disease.(25) Therefore, HAIC
may improve the quality of life and prolong the survival of
patients with HCC, although no definite data other than for
hepatic reserve was assessable here.
In conclusion, HAIC is effective for treating patients with
advanced HCC with a CPS = 7 or 8. The CPS of responders
also improved their outcomes, compared to nonresponders.
Although the present study is limited due to the retrospective
design and subjects, who were treated in a single center, our
findings are informative for determining treatment strategies or
designing future clinical trials of agents to treat patients with
advanced HCC.
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